Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes
NCT07926152, Not applicable, Not yet recruiting, German Diabetes Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT07926152 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 94 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | German Diabetes Center | ClinicalTrials.gov |
| Conditions | Type 2 Diabetes (T2DM), Obesity & Overweight, Sarcopenia | ClinicalTrials.gov |
| Interventions | Supervised exercise training, protein supplement, Standardized lifestyle counseling | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 37
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Contractile Thigh Muscle Volume | Baseline to week 24 | Change in contractile thigh skeletal muscle volume (mL), assessed by magnetic resonance imaging (MRI). Contractile thigh muscle volume is defined as the sum of the bilateral anterior (quadriceps femoris, sartorius, tensor fasciae latae) and posterior (gluteal muscles, iliopsoas, adductors, hamstrings) thigh skeletal muscle volume minus intramuscular adipose tissue (IMAT) volume. | ClinicalTrials.gov |
| Secondary | Percent Change in Contractile Thigh Skeletal Muscle Volume | Baseline and week 24 | Percent change in contractile thigh skeletal muscle volume from baseline to week 24, assessed by MRI. Contractile thigh muscle volume is defined as the sum of the bilateral anterior (quadriceps femoris, sartorius, tensor fasciae latae) and posterior (gluteal muscles, iliopsoas, adductors, hamstrings) thigh skeletal muscle volume minus intramuscular adipose tissue (IMAT) volume. | ClinicalTrials.gov |
| Secondary | Change in Body Weight | Baseline and week 24 | Change in body weight (kg) from baseline to week 24, measured on a calibrated scale in light clothing and without shoes. | ClinicalTrials.gov |
| Secondary | Change in Isometric Knee Extensor Strength | Baseline and week 24 | Change in maximal isometric knee extensor peak torque (Nm) from baseline to week 24, assessed at 60° knee flexion using an isometric dynamometer with Smartpanel software (highest value of 2-3 maximal voluntary trials). | ClinicalTrials.gov |
| Secondary | Change in Isometric Knee Flexor Strength | Baseline and week 24 | Change in maximal isometric knee flexor peak torque (Nm) from baseline to week 24, assessed at 60° knee flexion using an isometric dynamometer with Smartpanel software (highest value of 2-3 maximal voluntary trials). | ClinicalTrials.gov |
| Secondary | Change in 30-Second Chair Stand Test Performance | Baseline and week 24 | Change in the number of completed full stands within 30 seconds (arms crossed over the chest, no arm support) from baseline to week 24. | ClinicalTrials.gov |
| Secondary | Change in Usual Gait Speed | Baseline and week 24 | Change in usual gait speed (m/s) from baseline to week 24, assessed by a 10-meter walk test at self-selected pace (faster of two trials). | ClinicalTrials.gov |
| Secondary | Change in Handgrip Strength | Baseline and week 24 | Change in maximal handgrip strength (kg) from baseline to week 24, assessed using a hand dynamometer in a seated position with the elbow flexed at 90°. | ClinicalTrials.gov |
| Secondary | Change in Standing Balance | Baseline and week 24 | Change in standing balance from baseline to week 24, assessed by a graded balance test battery (side-by-side, semi-tandem and tandem stand, each up to 10 s; followed by single-leg stance with eyes open, up to 30 s, if the tandem stand is completed). Hold time (s) is recorded for each position. | ClinicalTrials.gov |
| Secondary | Change in Thigh Intramuscular Adipose Tissue Volume | Baseline and week 24 | Change in thigh intramuscular adipose tissue (IMAT) volume (mL) from baseline to week 24, assessed by MRI. | ClinicalTrials.gov |
| Secondary | Change in Visceral Adipose Tissue Volume | Baseline and week 24 | Change in visceral adipose tissue volume (L) from baseline to week 24, assessed by whole-body MRI (6-point mDIXON). | ClinicalTrials.gov |
| Secondary | Change in Subcutaneous Adipose Tissue Volume | Baseline and week 24 | Change in subcutaneous adipose tissue volume (L) from baseline to week 24, assessed by whole-body MRI (6-point mDIXON). | ClinicalTrials.gov |
| Secondary | Change in Hepatic Lipid Content (¹H-MRS) | Baseline and week 24 | Change in hepatic lipid content (%) from baseline to week 24, assessed by single-voxel proton magnetic resonance spectroscopy (¹H-MRS). | ClinicalTrials.gov |
| Secondary | Change in Liver Proton Density Fat Fraction (MRI-PDFF) | Baseline and week 24 | Change in liver proton density fat fraction (%) from baseline to week 24, assessed by quantitative MRI (6-echo Dixon). | ClinicalTrials.gov |
| Secondary | Change in Fat Mass | Baseline and week 24 | Change in total body fat mass (kg) from baseline to week 24, assessed by air-displacement plethysmography (BodPod) or bioelectrical impedance analysis (BIA), depending on center-specific availability. | ClinicalTrials.gov |
| Secondary | Change in Fat-Free Mass | Baseline and week 24 | Change in total body fat-free mass (kg) from baseline to week 24, assessed by air-displacement plethysmography (BodPod) or bioelectrical impedance analysis (BIA), depending on center-specific availability. | ClinicalTrials.gov |
| Secondary | Change in Whole-Body Insulin Sensitivity | Baseline and week 24 | Change in whole-body insulin sensitivity from baseline to week 24, assessed as insulin-stimulated glucose disposal (M-value) during the hyperinsulinemic-euglycemic clamp. | ClinicalTrials.gov |
| Secondary | Change in Liver Stiffness | Baseline and week 24 | Change in liver stiffness (kPa) from baseline to week 24, assessed by vibration-controlled transient elastography (FibroScan; median of 10 valid measurements). | ClinicalTrials.gov |
| Secondary | Change in Absolute Maximal Oxygen Uptake (VO2max) | Baseline and week 24 | Change in absolute VO2max (mL/min) from baseline to week 24, assessed by symptom-limited incremental cardiopulmonary exercise testing (CPET) on a cycle ergometer. | ClinicalTrials.gov |
| Secondary | Change in Relative Maximal Oxygen Uptake (VO2max) | Baseline and week 24 | Change in VO2max relative to body weight (mL/kg/min) from baseline to week 24, assessed by symptom-limited incremental cardiopulmonary exercise testing (CPET) on a cycle ergometer. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)